📖

TREM2 Protein (Triggering Receptor Expressed on Myeloid Cells 2)

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-trem2-protein

Related Entities

Metadata

slug	entities-trem2-protein
entity_type	entity
kg_node_id	None

🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (599)

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy90%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim90%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia90%

mentions🧪APOE-TREM2 Interaction Modulation90%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway90%

mentions🧪TREM2-Dependent Microglial Senescence Transition90%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia90%

related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia90%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination80%

mentions🧪TREM2-mediated microglial tau clearance enhancement80%

mentions🔬Immune atlas neuroinflammation analysis in neurodegeneration75%

mentions🔬Neuroinflammation and microglial priming in early Alzheimer&75%

mentions🔬Neuroinflammation and microglial priming in early AD — Analy75%

mentions🔬Does SYK activation provide neuroprotection or exacerbate ne75%

mentions🔬What are the optimal timing windows for TREM2 agonism vs ant75%

mentions🔬Analysis question not specified75%

mentions🧪APOE-TREM2 Interaction Modulation70%

mentions🧪TREM2-Mediated Selective Aggregate Clearance Pathway70%

mentions🧪TREM2-Dependent Microglial Senescence Transition70%

mentions🧪TREM2 Conformational Stabilizers for Synaptic Discrimination70%

mentions🧪TREM2-mediated microglial tau clearance enhancement70%

mentions🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia70%

mentions🧫s:** - GPR32 knockout in microglia should worsen neuroinflam70%

mentions🧫Proposed experiment from debate on Synaptic pruning by micro70%

mentions🧫s:** - Compare tau strain spreading in EXT1/EXT2 conditional70%

mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi70%

mentions🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti70%

mentions🧫Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy70%

mentions🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri70%

mentions🧫Experiment: Autoimmune Hypothesis Testing in AD70%

mentions🧫Blood Biomarker vs Tau PET for Treatment Monitoring70%

mentions🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi70%

mentions🧫DLB Cognitive Fluctuation Mechanism Experiment70%

mentions🧫Genetic Risk Modifiers in DLB Phenotype70%

mentions🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras70%

mentions🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud70%

mentions🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation70%

mentions🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr70%

mentions🧫Microglial Contributions to Huntington's Disease Pathog70%

mentions🧫Mixed Pathology Effects on Parkinson's Disease Progress70%

mentions🧫Prodromal Parkinson's Disease Biomarker Development — E70%

mentions🧫Progranulin Replacement Therapy for FTD — Vector Development70%

mentions🧫PSP and CBS Biomarker Validation Study70%

mentions🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo70%

mentions🧫Experiment Validation: In vitro ThT Assay70%

mentions🧫Tau ASO Therapy70%

mentions🧫Microglial TREM2 Agonist In Vivo Efficacy70%

mentions🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim70%

mentions🧫TREM2 Function in Alzheimer's Disease — From Risk Varia70%

mentions🧫TREM2 KO amyloid pathology study70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

related🧫Protein Aggregation Kinetic Validation Results70%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%

related🧫Experiment Validation: In vitro ThT Assay70%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas70%

related🔬Investigate prion-like spreading of tau pathology through co70%

related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%

related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%

related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%

related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%

related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%

related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%

related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%

related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%

related🧫Protein Aggregation Kinetic Validation Results70%

related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%

related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%

related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%

related🧫Experiment Validation: In vitro ThT Assay70%

related🧫Non-Motor Symptom Progression in Parkinson's Disease — 70%

related🧫Microglial TREM2 Agonist In Vivo Efficacy70%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim70%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia70%

see_also🧪TREM2 Conformational Stabilizers for Synaptic Discrimination70%

see_also🧪APOE-TREM2 Interaction Modulation70%

see_also🧪TREM2-Mediated Selective Aggregate Clearance Pathway70%

see_also🧪TREM2-Dependent Microglial Senescence Transition70%

see_also🧪TREM2-mediated microglial tau clearance enhancement70%

see_also🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia70%

related🔬Immune atlas neuroinflammation analysis in neurodegeneration67%

related🔬Neuroinflammation and microglial priming in early Alzheimer&67%

related🔬Neuroinflammation and microglial priming in early AD — Analy67%

related🔬Does SYK activation provide neuroprotection or exacerbate ne67%

related🔬What are the optimal timing windows for TREM2 agonism vs ant67%

related🔬Analysis question not specified67%

related🧪TREM2 Conformational Stabilizers for Synaptic Discrimination63%

related🧪TREM2-mediated microglial tau clearance enhancement63%

related🧫s:** - GPR32 knockout in microglia should worsen neuroinflam63%

related🧫Proposed experiment from debate on Synaptic pruning by micro63%

related🧫s:** - Compare tau strain spreading in EXT1/EXT2 conditional63%

related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi63%

related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti63%

related🧫Anti-Tau Antibody vs ASO/Gene Therapy — Comparative Efficacy63%

related🧫Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri63%

related🧫Experiment: Autoimmune Hypothesis Testing in AD63%

related🧫Blood Biomarker vs Tau PET for Treatment Monitoring63%

related🧫CBS vs PSP Phenotype Determinants — Single-Nucleus Multi-Omi63%

related🧫DLB Cognitive Fluctuation Mechanism Experiment63%

related🧫Genetic Risk Modifiers in DLB Phenotype63%

related🧫DLB Treatment Response Biomarkers — Predicting Cholinesteras63%

related🧫FTD Microglia Role: Protective vs Destructive Mechanism Stud63%

related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation63%

related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr63%

related🧫Microglial Contributions to Huntington's Disease Pathog63%

related🧫Mixed Pathology Effects on Parkinson's Disease Progress63%

related🧫Prodromal Parkinson's Disease Biomarker Development — E63%

related🧫Progranulin Replacement Therapy for FTD — Vector Development63%

related🧫PSP and CBS Biomarker Validation Study63%

related🧫Tau PET Pattern as Therapeutic Response Predictor in 4R-Tauo63%

related🧫Tau ASO Therapy63%

related🧫Microglial TREM2 Agonist In Vivo Efficacy63%

related🧫TREM2 Agonist Therapy for Parkinson's Disease — Experim63%

related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia63%

related🧫TREM2 KO amyloid pathology study63%

related🔬Investigate prion-like spreading of tau pathology through co63%

mentions🔬The disease-associated microglia (DAM) phenotype involves TR60%

mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen60%

related🧪APOE-TREM2 Interaction Modulation60%

related🧪TREM2-Mediated Selective Aggregate Clearance Pathway60%

related🧪TREM2-Dependent Microglial Senescence Transition60%

see_also📖Disease-Associated Microglia (DAM)60%

see_also📖ABCA1 - ATP-Binding Cassette Transporter A160%

see_also📖CLEC7A Gene60%

see_also📖GADD34 Gene60%

see_also📖ABCA7 (Redirect)60%

see_also📖ABI3 Gene60%

see_also📖ACE Gene60%

see_also📖adam1760%

see_also📖BICD2 Gene60%

see_also📖ERLIN1 Gene60%

see_also📖ERLIN2 — ER Lipid Raft Associated 260%

see_also📖KCTD7 Gene (CLN14)60%

see_also📖LIG460%

see_also📖LRP1060%

see_also📖MAN2B1 Gene60%

see_also📖MBD1 — Methyl-CpG Binding Domain Protein 160%

see_also📖PARP3 Gene60%

see_also📖PILRB Gene60%

see_also📖RIN3 — Rho GTPase-Activating Protein 2560%

see_also📖sepsocs60%

see_also📖SIGLEC9 — Sialic Acid Binding Ig-Like Lectin 960%

see_also📖UNC13B — UNC13 Homolog B (Munc13-2)60%

see_also📖Muscarinic Acetylcholine Receptor M2 (CHRM2)60%

see_also📖Complexin-2 Protein60%

see_also📖Dynamin-1 Protein (DNM1)60%

see_also📖GRPR Protein60%

see_also📖Huntingtin Protein (HTT)60%

see_also📖MLST8 Protein60%

see_also📖Munc18-1 Protein (STXBP1)60%

see_also📖PKR Protein (Protein Kinase R)60%

see_also📖PNKP Protein - Polynucleotide Kinase 3'-Phosphatase60%

see_also📖Tenascin-C Protein (Tenascin-C, TNC)60%

see_also📖TUBA4A Protein60%

see_also📖FTL Protein — Ferritin Light Chain60%

see_also📖SIGMA1 Gene60%

see_also📖ACSL4 Gene - Acyl-CoA Synthetase Long Chain Family Member 460%

see_also📖SIGLEC1 Gene60%

see_also📖Neurogenesis60%

see_also📖Pyroptosis in Neurodegeneration60%

see_also📖ST6GALNAC5 Gene60%

see_also📖St6galnac5 (ST6 N-acetylneuraminic acid alpha-2,6-sialyltran60%

see_also📖NLRP3 Inflammasome60%

see_also📖adam1060%

see_also📖4D Molecular Therapeutics60%

see_also📖Alzheimer's Digital Therapeutics Companies60%

see_also📖AD Exosome and Extracellular Vesicle Companies60%

see_also📖AD RNA-Based Therapeutics Companies60%

see_also📖Alectos Therapeutics Inc60%

see_also📖Aleza Therapeutics60%

see_also📖Alterity Therapeutics60%

see_also📖Amyl Therapeutics60%

see_also📖Appvian Therapeutics60%

see_also📖Arvinas Therapeutics60%

see_also📖Axial Therapeutics60%

see_also📖Axsome Therapeutics, Inc.60%

see_also📖BlueRock Therapeutics60%

see_also📖BrainStorm Cell Therapeutics Inc.60%

see_also📖Capricor Therapeutics60%

see_also📖Cerevel Therapeutics60%

see_also📖Chelsea Therapeutics60%

see_also📖Click Therapeutics60%

see_also📖Convelo Therapeutics60%

see_also📖CRISPR Therapeutics60%

see_also📖cyclo-therapeutics60%

see_also📖cynata-therapeutics60%

see_also📖Cytochrome Therapeutics60%

see_also📖Denali Therapeutics60%

see_also📖Encoded Therapeutics60%

see_also📖Evox Therapeutics60%

see_also📖Finch Therapeutics60%

see_also📖Fulcrum Therapeutics60%

see_also📖heqIX Therapeutics60%

see_also📖Iduna Therapeutics60%

see_also📖IFM Therapeutics60%

see_also📖Inception Therapeutics60%

see_also📖Karuna Therapeutics60%

see_also📖Koneqia Therapeutics60%

see_also📖Lexeo Therapeutics60%

see_also📖Lysoway Therapeutics60%

see_also📖Lyterian Therapeutics60%

see_also📖Monte Rosa Therapeutics60%

see_also📖Muna Therapeutics60%

see_also📖Neteo Therapeutics60%

see_also📖NeuBase Therapeutics60%

see_also📖NeuExo Therapeutics60%

see_also📖Neumora Therapeutics60%

see_also📖NeuroMito Therapeutics60%

see_also📖Paxos Therapeutics60%

see_also📖Parkinson's Disease Digital Therapeutics Companies60%

see_also📖pd-exosome-therapeutics60%

see_also📖PD RNA Therapeutics Companies60%

see_also📖Pear Therapeutics60%

see_also📖Pinteon Therapeutics60%

see_also📖Prevail Therapeutics60%

see_also📖Rodin Therapeutics60%

see_also📖Sage Therapeutics60%

see_also📖Sangamo Therapeutics60%

see_also📖Spark Therapeutics60%

see_also📖Spin Therapeutics60%

see_also📖Stoke Therapeutics60%

see_also📖Synaptic Therapeutics60%

see_also📖Synchronicity Therapeutics60%

see_also📖T3D Therapeutics60%

see_also📖Trefoil Therapeutics60%

see_also📖Vator Therapeutics Inc.60%

see_also📖Ventus Therapeutics60%

see_also📖Voyager Therapeutics60%

see_also📖VTV Therapeutics60%

see_also📖Yumanity Therapeutics60%

see_also📖MDS 2026 — Emerging Therapeutics in Parkinson's Disease60%

see_also📖alzheimers-disease60%

see_also📖Aleza Therapeutics60%

see_also📖Denali Therapeutics60%

see_also📖4R Tauopathy Therapeutics — Investment Landscape Analysis60%

see_also📖Adult Neurogenesis Therapeutics Investment Landscape60%

see_also📖Anti-Tau Therapeutics: Investment Landscape Analysis60%

see_also📖ER Stress & UPR Therapeutics Investment Landscape60%

see_also📖GLP-1 Receptor Agonist Therapeutics Investment Landscape60%

see_also📖Heat Shock Protein (HSP) Therapeutics for Neurodegeneration60%

see_also📖Lysosomal Dysfunction Therapeutics Investment Landscape60%

see_also📖Microbiome-Based Therapeutics for Neurodegeneration: Investm60%

see_also📖Mitochondrial Therapeutics Investment Landscape60%

see_also📖Peptide Therapeutics for Neurodegeneration — Investment Land60%

see_also📖Protein Aggregation Inhibitors for Neurodegeneration — Inves60%

see_also📖RNA Therapeutics: Investment Landscape Analysis60%

see_also📖Senolytic Therapeutics: Investment Landscape Analysis60%

see_also📖Anti-Amyloid Therapeutics: Successes, Failures, and Lessons 60%

see_also📖Denali Therapeutics60%

see_also📖Digital Therapeutics for Neurodegenerative Diseases60%

see_also📖RNA Editing Therapeutics60%

see_also📖therapeutics60%

see_also📖Anti-Amyloid Therapeutics60%

see_also📖Anti-Tau Therapeutics60%

see_also📖Exosome-Based Therapeutics for Neurodegenerative Diseases60%

see_also📖Mitochondrial Therapeutics60%

see_also📖Neurotrophic Factor Therapies for Neurodegenerative Diseases60%

see_also📖TGF-beta Signaling Therapies for Neurodegeneration60%

see_also📖Microglial Phagocytosis in Neurodegeneration60%

see_also📖IDUA Gene60%

see_also📖ANO3 Gene60%

see_also📖BMPR1A — Bone Morphogenetic Protein Receptor Type 1A60%

see_also📖PFN1 Gene60%

see_also📖PRDX2 — Peroxiredoxin 260%

see_also📖RAD23B Gene60%

see_also📖SCFD160%

see_also📖USF1 — Upstream Transcription Factor 160%

see_also📖ZNRNP1 — Zinc Finger, RNGTT Type 160%

see_also📖Galectin-3 Protein60%

related🔬The disease-associated microglia (DAM) phenotype involves TR54%

related🔬Comprehensive analysis of immune cell subtypes in neurodegen54%

mentions🔬What are the mechanisms underlying digital biomarkers and ai50%

mentions🔬What are the mechanisms underlying neuroinflammation resolut50%

mentions🔬What are the mechanisms underlying mechanistic role of apoe 50%

mentions🔬What are the mechanisms underlying synaptic pruning by micro50%

mentions🔬What gene expression changes in the aging mouse brain predic50%

mentions🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

mentions🔬Investigate prion-like spreading of tau pathology through co50%

mentions🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

mentions🧪Temporal Decoupling via Circadian Clock Reset50%

mentions🧪Purinergic Signaling Polarization Control50%

mentions🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration50%

mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer50%

mentions🧪Mitochondrial SPM Synthesis Platform Engineering50%

mentions🧪APOE Isoform Conversion Therapy50%

mentions🧪Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu50%

mentions🧪CYP46A1 Overexpression Gene Therapy50%

mentions🧪Enteric Nervous System Prion-Like Propagation Blockade50%

mentions🧪Age-Dependent Complement C4b Upregulation Drives Synaptic Vu50%

mentions🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition50%

mentions🧪Targeted Butyrate Supplementation for Microglial Phenotype M50%

mentions🧪Senescent Microglia Resolution via Maresins-Senolytics Combi50%

mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%

mentions🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists50%

mentions🧪Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics50%

mentions🧪APOE-Dependent Autophagy Restoration50%

mentions🧪SASP-Mediated Complement Cascade Amplification50%

mentions🧪Complement C1q Subtype Switching50%

mentions🧪Microglial Purinergic Reprogramming50%

mentions🧪Autophagosome Maturation Checkpoint Control50%

mentions🧪Prefrontal sensory gating circuit restoration via PV interne50%

mentions🧪Ocular Immune Privilege Extension50%

mentions🧪Optogenetic Microglial Deactivation via Engineered Inhibitor50%

mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%

mentions🧪Astrocyte-Mediated Neuronal Epigenetic Rescue50%

mentions🧪Blood-Brain Barrier SPM Shuttle System50%

mentions🧪Stress Granule Phase Separation Modulators50%

mentions🧪TFAM overexpression creates mitochondrial donor-recipient gr50%

mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%

mentions🧪Membrane Cholesterol Gradient Modulators50%

mentions🧪Temporal TET2-Mediated Hydroxymethylation Cycling50%

mentions🧪Chromatin Accessibility Restoration via BRD4 Modulation50%

mentions🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri50%

mentions🧪Senescence-Associated Myelin Lipid Remodeling50%

mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%

mentions🧪Competitive APOE4 Domain Stabilization Peptides50%

mentions🧪Reelin-Mediated Cytoskeletal Stabilization Protocol50%

mentions🧪Multi-Modal CRISPR Platform for Simultaneous Editing and Mon50%

mentions🧪Ephrin-B2/EphB4 Axis Manipulation50%

mentions🧪Phase-Separated Organelle Targeting50%

mentions🧪Purinergic P2Y12 Inverse Agonist Therapy50%

mentions🧪Microbiome-Derived Tryptophan Metabolite Neuroprotection50%

mentions🧪RNA Granule Nucleation Site Modulation50%

mentions🧪Complement C1QA Spatial Gradient in Cortical Layers50%

mentions🧪APOE Isoform Expression Across Glial Subtypes50%

mentions🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro50%

mentions🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors50%

mentions🧪Circadian Rhythm Entrainment of Reactive Astrocytes50%

mentions🧪Circadian Clock-Autophagy Synchronization50%

mentions🧪Metabolic Switch Targeting for A1→A2 Repolarization50%

mentions🧪Lysosomal Positioning Dynamics Modulation50%

mentions🧪PARP1 Inhibition Therapy50%

mentions🧪Perforant Path Presynaptic Terminal Protection Strategy50%

mentions🧪AMPK hypersensitivity in astrocytes creates enhanced mitocho50%

mentions🧪Glycine-Rich Domain Competitive Inhibition50%

mentions🧪Low Complexity Domain Cross-Linking Inhibition50%

mentions🧪Heat Shock Protein 70 Disaggregase Amplification50%

mentions🧪Serine/Arginine-Rich Protein Kinase Modulation50%

mentions🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto50%

mentions🧪Magnetosonic-Triggered Transferrin Receptor Clustering50%

related🔬What are the mechanisms underlying selective vulnerability o50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬Investigate how lipid raft composition (cholesterol metaboli50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

related🔬What are the mechanisms underlying perivascular spaces and g50%

related🧫Proposed experiment from debate on Synaptic pruning by micro50%

related🔬Tau propagation mechanisms and therapeutic interception poin50%

related🔬What cell types are most vulnerable in Alzheimer's Dise50%

related🔬Cell type vulnerability in Alzheimer's Disease (SEA-AD 50%

related🔬What are the mechanisms underlying selective vulnerability o50%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp50%

related🔬What are the mechanisms underlying tdp-43 phase separation t50%

related🔬What are the mechanisms underlying astrocyte reactivity subt50%

related🔬What are the mechanisms underlying blood-brain barrier trans50%

related🔬What are the mechanisms underlying microglia-astrocyte cross50%

related🔬What are the mechanisms underlying apoe4 structural biology 50%

related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%

related🔬What are the mechanisms underlying digital biomarkers and ai50%

related🔬What are the mechanisms underlying senolytic therapy for age50%

related🔬What are the mechanisms underlying neuroinflammation resolut50%

related🔬What are the mechanisms underlying what are the mechanisms b50%

related🔬What are the mechanisms underlying protein aggregation cross50%

related🔬What are the mechanisms underlying mechanistic role of apoe 50%

related🔬Investigate how lipid raft composition (cholesterol metaboli50%

related🔬What are the mechanisms underlying rna binding protein dysre50%

related🔬What are the mechanisms underlying synaptic pruning by micro50%

related🔬What are the mechanisms underlying mitochondrial transfer be50%

related🔬What are the mechanisms underlying perivascular spaces and g50%

related🔬Analyze circuit-level changes in neurodegeneration using All50%

related🔬What gene expression changes in the aging mouse brain predic50%

related🔬CRISPR-based therapeutic approaches for neurodegenerative di50%

related🔬Epigenetic reprogramming in aging neurons50%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%

related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%

related🔬What are the most promising therapeutic strategies for targe50%

related🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br50%

related🔬RNA binding protein dysregulation across ALS FTD and AD50%

see_also📖sTREM2 (Soluble TREM2) - Microglial Biomarker50%

see_also📖sTREM2 (Soluble TREM2) - Biomarker50%

see_also📖al002-trem2-agonist-alzheimers50%

see_also📖TREM2 Gene50%

see_also📖TREM2 in Amyotrophic Lateral Sclerosis45%

see_also📖TREM2 in Frontotemporal Dementia45%

see_also📖TREM2 Gene-Mechanism-Therapy Chain — From Genetic Risk to Th45%

mentions🔬What are the most promising therapeutic strategies for targe40%

mentions🔬What are the mechanisms underlying protein aggregation cross40%

mentions🔬What are the mechanisms underlying rna binding protein dysre40%

mentions🔬RNA binding protein dysregulation across ALS FTD and AD40%

mentions🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

related🧪Netrin-1 Gradient Restoration40%

related🧪Oligodendrocyte White Matter Vulnerability40%

related🧪Smartphone-Detected Motor Variability Correction40%

related🧪Circadian-Synchronized Proteostasis Enhancement40%

related🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration40%

related🧪Selective HDAC3 Inhibition with Cognitive Enhancement40%

related🧪HSP90-Tau Disaggregation Complex Enhancement40%

related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer40%

related🧪Mitochondrial SPM Synthesis Platform Engineering40%

related🧪APOE Isoform Conversion Therapy40%

related🧪VCP-Mediated Autophagy Enhancement40%

related🧪Mitochondrial RNA Granule Rescue Pathway40%

related🧪Multi-Modal Stress Response Harmonization40%

related🧪Complement C1q Mimetic Decoy Therapy40%

related🧪Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu40%

related🧪Liquid-Liquid Phase Separation Modifier Therapy40%

related🧪Retinal Vascular Microcirculation Rescue40%

related🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition40%

related🧪Senescent Microglia Resolution via Maresins-Senolytics Combi40%

related🧪APOE4 Allosteric Rescue via Small Molecule Chaperones40%

related🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists40%

related🧪Nutrient-Sensing Epigenetic Circuit Reactivation40%

related🧪LRP1-Dependent Tau Uptake Disruption40%

related🧪Cryptic Exon Silencing Restoration40%

related🧪Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics40%

related🧪APOE-Dependent Autophagy Restoration40%

related🧪Glycosaminoglycan Template Disruption Approach40%

related🧪Extracellular Vesicle Biogenesis Modulation40%

related🧪APOE-Mediated Synaptic Lipid Raft Stabilization40%

related🧪Complement C1q Subtype Switching40%

related🧪Proteostasis Enhancement via APOE Chaperone Targeting40%

related🧪Microglial Purinergic Reprogramming40%

related🧪Glymphatic System-Enhanced Antibody Clearance Reversal40%

related🧪Prefrontal sensory gating circuit restoration via PV interne40%

related🧪Chaperone-Mediated APOE4 Refolding Enhancement40%

related🧪Sphingolipid Metabolism Reprogramming40%

related🧪Ocular Immune Privilege Extension40%

related🧪Synaptic Vesicle Tau Capture Inhibition40%

related🧪RNA-Binding Competition Therapy for TDP-43 Cross-Seeding40%

related🧪Optogenetic Microglial Deactivation via Engineered Inhibitor40%

related🧪Piezoelectric Nanochannel BBB Disruption40%

related🧪Circadian-Synchronized LRP1 Pathway Activation40%

related🧪Axonal RNA Transport Reconstitution40%

related🧪Circadian-Gated Maresin Biosynthesis Amplification40%

related🧪Synthetic Biology BBB Endothelial Cell Reprogramming40%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%

related🧪Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption40%

related🧪Astrocyte-Mediated Neuronal Epigenetic Rescue40%

related🧪Blood-Brain Barrier SPM Shuttle System40%

related🧪Stress Granule Phase Separation Modulators40%

related🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction40%

related🧪Pharmacological Enhancement of APOE4 Glycosylation40%

related🧪Targeted APOE4-to-APOE3 Base Editing Therapy40%

related🧪Complement-Mediated Synaptic Pruning Dysregulation40%

related🧪Temporal TET2-Mediated Hydroxymethylation Cycling40%

related🧪Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Th40%

related🧪Chromatin Accessibility Restoration via BRD4 Modulation40%

related🧪Digital Twin-Guided Metabolic Reprogramming40%

related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides40%

related🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri40%

related🧪Partial Neuronal Reprogramming via Modified Yamanaka Cocktai40%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%

related🧪Glial Glycocalyx Remodeling Therapy40%

related🧪R-Loop Resolution Enhancement Therapy40%

related🧪Aquaporin-4 Polarization Rescue40%

related🧪HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor40%

related🧪APOE4-Selective Lipid Nanoemulsion Therapy40%

related🧪Competitive APOE4 Domain Stabilization Peptides40%

related🧪Transglutaminase-2 Cross-Linking Inhibition Strategy40%

related🧪Vocal Cord Neuroplasticity Stimulation40%

related🧪TFEB-PGC1α Mitochondrial-Lysosomal Decoupling40%

related🧪Ephrin-B2/EphB4 Axis Manipulation40%

related🧪Nucleolar Stress Response Normalization40%

related🧪Cross-Seeding Prevention Strategy40%

related🧪Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution40%

related🧪Purinergic P2Y12 Inverse Agonist Therapy40%

related🧪Trans-Synaptic Adhesion Molecule Modulation40%

related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation40%

related🧪Complement C1QA Spatial Gradient in Cortical Layers40%

related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation40%

related🧪APOE Isoform Expression Across Glial Subtypes40%

related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro40%

related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli40%

related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK40%

related🧪Temporal Decoupling via Circadian Clock Reset40%

related🧪Purinergic Signaling Polarization Control40%

related🧪Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration40%

related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer40%

related🧪Mitochondrial SPM Synthesis Platform Engineering40%

related🧪Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu40%

related🧪CYP46A1 Overexpression Gene Therapy40%

related🧪Enteric Nervous System Prion-Like Propagation Blockade40%

related🧪Metabolic Reprogramming via Microglial Glycolysis Inhibition40%

related🧪Senescent Microglia Resolution via Maresins-Senolytics Combi40%

related🧪APOE4 Allosteric Rescue via Small Molecule Chaperones40%

related🧪Microglial Efferocytosis Enhancement via GPR32 Superagonists40%

related🧪Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics40%

related🧪SASP-Mediated Complement Cascade Amplification40%

related🧪Complement C1q Subtype Switching40%

related🧪Microglial Purinergic Reprogramming40%

related🧪Heat Shock Protein 70 Disaggregase Amplification40%

related🧪Autophagosome Maturation Checkpoint Control40%

related🧪Prefrontal sensory gating circuit restoration via PV interne40%

related🧪Ocular Immune Privilege Extension40%

related🧪Optogenetic Microglial Deactivation via Engineered Inhibitor40%

related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%

related🧪Astrocyte-Mediated Neuronal Epigenetic Rescue40%

related🧪Blood-Brain Barrier SPM Shuttle System40%

related🧪Stress Granule Phase Separation Modulators40%

related🧪TFAM overexpression creates mitochondrial donor-recipient gr40%

related🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction40%

related🧪Membrane Cholesterol Gradient Modulators40%

related🧪Circadian Glymphatic Entrainment via Targeted Orexin Recepto40%

related🧪Temporal TET2-Mediated Hydroxymethylation Cycling40%

related🧪Magnetosonic-Triggered Transferrin Receptor Clustering40%

related🧪Chromatin Accessibility Restoration via BRD4 Modulation40%

related🧪Fractalkine Axis Amplification via CX3CR1 Positive Allosteri40%

related🧪Senescence-Associated Myelin Lipid Remodeling40%

related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%

related🧪Competitive APOE4 Domain Stabilization Peptides40%

related🧪Reelin-Mediated Cytoskeletal Stabilization Protocol40%

related🧪Serine/Arginine-Rich Protein Kinase Modulation40%

related🧪Ephrin-B2/EphB4 Axis Manipulation40%

related🧪Phase-Separated Organelle Targeting40%

related🧪Purinergic P2Y12 Inverse Agonist Therapy40%

related🧪Microbiome-Derived Tryptophan Metabolite Neuroprotection40%

related🧪RNA Granule Nucleation Site Modulation40%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%

related🔬Tau propagation mechanisms and therapeutic interception poin40%

related🔬SPMs (resolvins, protectins, maresins) from omega-3s may pro40%

related🔬What are the mechanisms underlying neuroinflammation resolut40%

related🔬Synaptic pruning by microglia in early AD40%

related🔬Analyze circuit-level changes in neurodegeneration using All40%

related🔬Circuit-level neural dynamics in neurodegeneration — Analysi40%

related🔬What are the mechanisms underlying digital biomarkers and ai40%

related🔬Can speech, gait, retinal imaging, sleep, and smartphone dat40%

related🔬What are the mechanisms underlying blood-brain barrier trans40%

related🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%

related🔬What are the mechanisms underlying rna binding protein dysre40%

related🔬RNA binding protein dysregulation across ALS FTD and AD40%

related🔬Gene expression changes in aging mouse brain predicting neur40%

related🔬PSP and CBD both involve 4R-tau but produce distinct neuropa40%

related🔬What are the mechanisms underlying protein aggregation cross40%

related🔬Analysis question not specified40%

related🔬Epigenetic reprogramming in aging neurons40%

related🔬What are the mechanisms underlying synaptic pruning by micro40%

related🔬What are the mechanisms underlying mechanistic role of apoe 40%

related🔬Analysis question not specified40%

related🔬Neuroinflammation and microglial priming in early Alzheimer&40%

related🔬What gene expression changes in the aging mouse brain predic40%

related🔬What are the mechanisms underlying apoe4 structural biology 40%

related🔬APOE4 differs from APOE3 by C112R causing domain interaction40%

related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc40%

mentions🔬What are the mechanisms underlying selective vulnerability o35%

mentions🔬What are the mechanisms underlying 4r-tau strain-specific sp35%

mentions🔬What are the mechanisms underlying tdp-43 phase separation t35%

mentions🔬What are the mechanisms underlying astrocyte reactivity subt35%

mentions🔬What are the mechanisms underlying blood-brain barrier trans35%

mentions🔬What are the mechanisms underlying microglia-astrocyte cross35%

mentions🔬What are the mechanisms underlying apoe4 structural biology 35%

mentions🔬What are the mechanisms underlying autophagy-lysosome pathwa35%

mentions🔬What are the mechanisms underlying senolytic therapy for age35%

mentions🔬What are the mechanisms underlying what are the mechanisms b35%

mentions🔬Investigate how lipid raft composition (cholesterol metaboli35%

mentions🔬What are the mechanisms underlying mitochondrial transfer be35%

mentions🔬Analyze circuit-level changes in neurodegeneration using All35%

mentions🔬What gene expression changes in the aging mouse brain predic35%

mentions🔬CRISPR-based therapeutic approaches for neurodegenerative di35%

mentions🔬Epigenetic reprogramming in aging neurons35%

related🔬What are the mechanisms underlying 4r-tau strain-specific sp24%